Sandostatin

Known as: Sandostatine 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1986-2018
0102019862018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
BACKGROUND/AIMS The overexpression of somatostatin receptors in the liver of some patients with hepatocellular carcinoma is well… (More)
Is this relevant?
1996
1996
A stable and sustained suppression of growth hormone (GH) secretion was noted in 101 patients treated long term with individual… (More)
Is this relevant?
1995
1995
Octreotide (Sandostatin) is a synthetic analog of somatostatin, an endogenous GH inhibitory peptide that has been used as an… (More)
Is this relevant?
1995
1995
Sandostatin LAR is a sustained release formulation of octreotide that has been developed by microencapsulating the drug with… (More)
Is this relevant?
1993
1993
One hundred and fifteen gastroenteropancreatic (GEP) patients with malignant endocrine tumours entered a prospective multicentre… (More)
Is this relevant?
1993
1993
A prospective study was performed to determine the efficacy of octreotide (Sandostatin®; SMS 201–995) 200 μg tid in controlling… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
1993
1993
The mechanism and response to treatment of severe life-threatening hypoglycaemia (plasma glucose 1.15 +/- 0.73 mM/l [+/- SD]) was… (More)
Is this relevant?
1989
1989
Recently somatostatin analogues were successfully used to control insulin-induced hypoglycemia in patients with insulinoma. We… (More)
Is this relevant?
1989
1989
The distribution, excretion, and metabolism of Sandostatin, a long-acting octapeptide analogue of somatostatin, have been studied… (More)
Is this relevant?
1988
1988
Fifteen acromegalic patient were treated for a mean of 96 weeks with 200-300 micrograms Sandostatin per day. The mean 24 h GH… (More)
Is this relevant?